- Adenosine signaling has emerged as a key immunosuppressive mechanism in the tumor microenvironment, and CD73 is a rate-limiting enzyme for adenosine production.
- Uliledlimab is a differentiated CD73 antibody that binds to a unique epitope to achieve complete inhibition of CD73 and its anti-tumor activity is currently being evaluated in clinical studies in combination with checkpoint inhibitors.
- Here we investigated the immune modulatory mechanism of uliledlimab in different cell subsets and pathways to explore new therapeutic combinations of uliledlimab for cancer treatment.
